Monoclonal mouse anti human G-CSF

HomeAntibodiesmonoclonals

Monoclonal mouse anti human G-CSF

$99.00 – $149.00

SKU: RMA09919 Category: monoclonals Tags: C17orf33, CSF3, Filgrastim, g-csf, gcsf, Lenograstim, P09919, Pluripoietin

Description

Methods (1)


accession	P09919

Applications	ELISA: This antibody can be used as capture antibody at 2 μg/mL jointly with biotinylated Anti GCSF polyclonal detection antibody to detect Human GCSF. The detection limit for recombinant Human G-CSF is approximately 0.1 ng/well. Western blot:This monoclonal antibody has been tested in WB analysis of human G-CSF . A suitable range of concentrations of this antibody for WB detection is 1-2 µg/ml. The detection limit for Recombinant Human G-CSF is 1.0-2.0 ng/lane, under reducing or non-reducing conditions.
Source	This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with recombinant E. coli-derived Human GCSF.
Species reactivity	Human G-CSF
Purification	The IgG fraction of the tissue culture supernatant was purified by Protein A affinity chromatography.
Presentation	Prepared from sterile filtered solution at a concentration of 1mg/ml in PBS with 5% trehalose.
Reconstitution	A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers
Storage	This antibody can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage	This antibody product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

Interactor	P40223
Molecular function	Cytokine
Molecular function	Growth-factor

Methods


In vivo tumor growth and G-CSF studies Female BALB/c mice were injected orthotopically in an abdominal mammary gland with 5×10⁴ 4T1 cells. Female B6 mice were injected similarly with 5×10⁵ AT-3 cells, including those cell lines used in the knockdown studies. For the G-CSF over-expression tumor studies, syngeneic BALB/c mice were injected subcutaneously into the flank with 4×10⁵ CMS4 cells. In the admix experiments, 5×10⁴ 4T1 tumor cells were mixed with MACS-purified, MHC-matched CD11b⁺Gr-1⁺ cells at a 2∶1 ratio, respectively, prior to orthotopic implantation. Spleens, serum and tumor tissue were recovered, as appropriate. For the G-CSF blockade studies, B6 mice were injected orthotopically, and on day 7 when tumors became palpable, mice were injected intraperitoneally with 10 µg of either neutralizing anti-G-CSF mAb or rat IgG isotype for 8-consecutive days, as described in vivo depletion experiments, BALB/c mice were injected ip with anti-Gr-1 Ab (cloneB6-8C5, , ) or control Ab (at IgG2b clone LTF-2,… Female BALB/c mice were injected orthotopically in an abdominal mammary gland with 5×10⁴ 4T1 cells. Female B6 mice were injected similarly with 5×10⁵ AT-3 cells, including those cell lines used in the knockdown studies. For the G-CSF over-expression tumor studies, syngeneic BALB/c mice were injected subcutaneously into the flank with 4×10⁵ CMS4 cells. In the admix experiments, 5×10⁴ 4T1 tumor cells were mixed with MACS-purified, MHC-matched CD11b⁺Gr-1⁺ cells at a 2∶1 ratio, respectively, prior to orthotopic implantation. Spleens, serum and tumor tissue were recovered, as appropriate. For the G-CSF blockade studies, B6 mice were injected orthotopically, and on day 7 when tumors became palpable, mice were injected intraperitoneally with 10 µg of either neutralizing anti-G-CSF mAb or rat IgG isotype for 8-consecutive days, as described in vivo depletion experiments, BALB/c mice were injected ip with anti-Gr-1 Ab (cloneB6-8C5, , ) or control Ab (at IgG2b clone LTF-2, , ). Antibodies were administered at 200 µg/mouse once tumors became palpable, and continued twice weekly for the duration of the experiment, similarly as described ³ or for other health considerations. Tumor growth was measured 2 – 3 times/week in two dimensions and tumor volume was calculated using the formula (width²×length)/2. For recombinant G-CSF in vivo studies, mice were injected subcutaneously with recombinant G-CSF (10 µg/day, , ) for 5 consecutive days and serum/tissues collected, similarly as described Read more